Does Estradiol Level in Platelet-Rich Plasma Improve Efficacy of Androgenic Alopecia Treatment?

Basit Öğe Kaydı
dc.contributor.authorInce, Bilsev
dc.contributor.authorKendir, Munur Selcuk
dc.contributor.authorKilinc, Ibrahim
dc.contributor.authorAvunduk, Mustafa Cihat
dc.contributor.authorDadaci, Mehmet
dc.contributor.authorSavaci, Nedim
dc.date.accessioned2024-02-23T14:20:59Z
dc.date.available2024-02-23T14:20:59Z
dc.date.issued2020
dc.departmentNEÜen_US
dc.description.abstractBackground: Although some studies in the literature report that autologous and homologous platelet-rich plasma (PRP) can be employed in the treatment of androgenic alopecia (AGA), no study, to the authors' knowledge, has examined the estrogen concentration of prepared PRP. Objectives: The authors aimed to determine the presence of estrogen in PRP and to investigate the effect of estrogen concentration of PRP on AGA treatment. Methods: Between 2017 and 2018, 30 male patients with hair loss complaints were included in this prospective study. Autologous PRP was injected in patients in Group 1. Homologous PRP with high estrogen levels was injected in the patients in Group 2. PRP was injected in both groups 4 times at 0,1, 3, and 6 months. The obtained photographs were evaluated and hair densities of each patient at controls were calculated. Results: The mean estrogen level measured in PRP was statistically significantly higher in Group 2. In both groups, the increase in hair density was observed from the first month, but this increase was statistically significantly higher in all controls in Group 2. In Group 2, there was a statistically significant increase in the 1st and 3rd months compared with the previous control, but there was no difference between the 6th and 12th months and the 3rd month. Conclusions: Increased hair density is greater and earlier in the group receiving estrogen-rich PRP than in the group utilizing autologous PRP. The authors think that estrogen-rich PRP may be employed in the treatment of AGA in the presence of an appropriate donor.en_US
dc.identifier.doi10.1093/asj/sjaa155
dc.identifier.endpageNP618en_US
dc.identifier.issn1090-820X
dc.identifier.issn1527-330X
dc.identifier.issue11en_US
dc.identifier.pmid32511689en_US
dc.identifier.scopus2-s2.0-85094685239en_US
dc.identifier.scopusqualityQ1en_US
dc.identifier.startpageNP613en_US
dc.identifier.urihttps://doi.org/10.1093/asj/sjaa155
dc.identifier.urihttps://hdl.handle.net/20.500.12452/13397
dc.identifier.volume40en_US
dc.identifier.wosWOS:000592519100001en_US
dc.identifier.wosqualityQ1en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherOxford Univ Press Incen_US
dc.relation.ispartofAesthetic Surgery Journalen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subject[Keyword Not Available]en_US
dc.titleDoes Estradiol Level in Platelet-Rich Plasma Improve Efficacy of Androgenic Alopecia Treatment?en_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu